Stocks · News reference

RBC Raises Price Target on GRAIL, Inc.

2026-11-05 19:03:48 UTC

RBC increased its price target for GRAIL, Inc. to $100 from $84 while maintaining a Sector Perform rating.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Benzinga2026-11-05 19:27:35 UTCBenzinga Newsdesk
RBC Capital Maintains Sector Perform on GRAIL, Raises Price Target to $100
GRAL
Fiscal.ai2026-11-05 12:32:24 UTC
GRAIL, Inc. 12-Month Price Target Raised to $134.33
Analysts have increased the 12-month price target for GRAIL, Inc. to $134.33, maintaining a consensus "Buy" rating.
GRAL
Fiscal.ai2026-11-04 23:02:03 UTC
GRAIL Reports Third Quarter 2026 Financial Results
GRAIL, Inc. released its financial results for the third quarter of 2026.
GRAL
Benzinga2026-11-04 21:05:47 UTCBenzinga Insights
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the Q3 earnings
ADMA ARQT CRIS CUE EQ
Benzinga2026-11-04 21:03:26 UTCBenzinga Newsdesk
GRAIL Q3 EPS $(2.21) Beats $(2.55) Estimate, Sales $37.269M Miss $44.346M Estimate
GRAL
Fiscal.ai2026-10-27 22:02:11 UTC
GRAIL to Present at the UBS Global Healthcare Conference
GRAIL, Inc. announced that company management is scheduled to present at the upcoming UBS Global Healthcare Conference in Palm Beach, Florida.
GRAL